Live Webinar on Dec 4! Cut Through the AI Noise: A Framework for Canadian Clinicians. Register now
[searchwp_form id="1"]

Loading results ...

HTA2: Advancing HTA Expertise in Saudi Arabia Forum

Advancing HTA Expertise in Saudi Arabia Forum

June 5-6. 2026

HTA2: Advancing HTA Expertise in Saudi Arabia Forum is a 5-month applied training program that builds on HTA1 and takes participants from theory to practice. Through virtual workshops series, online simulations, and a live capstone summit in Riyadh, delegates learn how to develop, evaluate, and present HTA dossiers that align with MOH, SFDA, and CNHI priorities and support Vision 2030 health system goals.

By the end of this program, participants will be able to:

  • Develop a complete HTA submission dossier that meets KSA-specific requirements
  • Apply MOH and SFDA evaluation criteria to review and score HTA submissions
  • Perform Saudi-specific budget impact analysis using local data and assumptions
  • Translate evidence into clear, policy-aligned value narratives for payers and decision makers
  • Collaborate in cross-functional teams to support pricing, reimbursement, and procurement decisions across the KSA HTA ecosystem

Sign up for all HTA2 modules using the registration form. Please keep the following in mind:

  • Inclusion Criteria: Participation in the program is subject to specific inclusion criteria.
  • Progressive Learning: You may be required to pass a post-event knowledge check after each module to qualify for the next.
  • Capstone Summit: Please note that there are limited spots available for the live capstone summit in Riyadh.

Module 1: Strengthening Foundations for Clear and Effective HTA Communication
January 22, 2026 | 6:00 PM - 8:00 PM AST (Riyadh)

This introductory session provides a short refresh of key Wave 1 concepts, followed by a focused workshop on effective communication and dossier writing. Participants will learn how to present evidence clearly, structure dossier components, and align communication with KSA HTA expectations before moving into the more technical modules that follow

Objectifs d'apprentissage

By the end of this workshop, participants will be able to:

  • Briefly revisit core Wave 1 foundations to ensure a shared starting point
  • Apply communication techniques to improve clarity, consistency, and alignment in HTA submissions
  • Organize dossier content using structured, policy-aligned formats
  • Strengthen writing skills for PICO framing, evidence summarization, and value communication
  • Identify common communication pitfalls and how to avoid them when preparing HTA materials
Did you miss Module 1? You can catch up by viewing the recording today!
  • Have an MDBriefCase account? Click here to watch Module 1
  • Have an RxBriefCase account (for pharmacists)? Click here to watch Module 1
Faculté
Prof. David Strain
Prof. David Strain
MB, ChB, BSc (Hons) MD, FRCP
Dr. Abeer Al Rabayah
Dr. Abeer Al Rabayah
BSc Pharmacy, MBA, MSc
Dr. Hajer Al-Mudaiheem
Dr. Hajer Al-Mudaiheem
Pharm.D, MSc, Clinical Pharmacy

Module 2: Building the Evidence Blueprint
February 13, 2026 | 6:00 PM - 8:00 PM AST (Riyadh)

This module introduces participants to the strategic use of data when planning and developing an HTA submission. Building on the communication and writing foundations from Workshop 1, this session focuses on how to identify, select, and frame the evidence needed for a strong, KSA-aligned dossier. Participants will learn how to determine the right data sources, anticipate payer and evaluator expectations, and create a coherent data plan that supports later modules on budget impact, value narrative, and evaluation.

Objectifs d'apprentissage

By the end of this workshop, participants will be able to:

  • Identify the clinical, economic, and real-world data types required for KSA HTA submissions
  • Map evidence needs to SFDA/MOH evaluation criteria to ensure alignment from the outset
  • Develop a structured data plan that links PICO framing to the analyses completed later in the program (BIA, value narrative, and evaluation lens)
  • Understand how data gaps, limitations, and local assumptions influence the strength and credibility of a submission
  • Organize evidence inputs in a way that supports the full dossier development process and prepares teams for Module 3 (Budget Impact)
Did you miss Module 2? You can catch up by viewing the recording today!
  • Have an MDBriefCase account? Click here to watch Module 2
  • Have an RxBriefCase account (for pharmacists)? Click here to watch Module 2
Faculté
Dr. Abeer Al Rabayah
Dr. Abeer Al RabayahBSc Pharmacy, MBA, MSc
Dr. Fatimah Alyami
Dr. Fatimah AlyamiBPharm, MS, PhD

Module 3: Translating Evidence into Budget Decisions
March 2, 2026 | 9:00 PM - 10:00 PM AST (Riyadh)

In this module, participants learn how to translate evidence into a clear, Saudi-specific Budget Impact Analysis (BIA) — a core component of any HTA submission. This session teaches delegates how to construct credible budget impact projections that support policymaker and evaluator interpretations. The goal is to equip participants with the skills needed to produce decision-relevant BIAs that support payer alignment, pricing discussions, and later stages of dossier development.

Objectifs d'apprentissage

By the end of this workshop, participants will be able to:

  • Determine the essential data elements, parameters, and assumptions required for a KSA-aligned BIA
  • Apply local epidemiology, utilization patterns, and cost structures to construct credible budget impact projections
  • Translate evidence into budget scenarios that support policymaker and evaluator interpretation
  • Understand how BIA outputs influence value judgments, procurement decisions, and SFDA/MOH evaluation criteria
  • Prepare BIA components that integrate seamlessly into Module 4 (Value Narrative) and Module 5 (Dossier Submission)
Did you miss Module 3? You can catch up by viewing the recording today!
  • Have an MDBriefCase account? Click here to watch Module 3
  • Have an RxBriefCase account (for pharmacists)? Click here to watch Module 3
Faculté
Dr. Wejdan Aburas
Dr. Wejdan Aburas PharmD, BCPS

Module 4: Communicating Value with Clarity and Purpose
April 23, 2026 | 6:00 PM - 7:00 PM AST (Riyadh)

Module 4 teaches participants how to craft a clear and persuasive value narrative that connects clinical evidence, economic findings, and local system priorities. Building on the BIA developed in Module 3 and the evidence planning from Module 2, this session focuses on how to communicate value in a way that aligns with the needs of SFDA, MOH, and other decision makers. Participants learn how to frame benefits, address uncertainties, and present a coherent story that strengthens the overall dossier.

By the end of this workshop, participants will be able to:

  • Translate clinical, economic, and real-world evidence into a clear value story that aligns with KSA decision-maker expectations
  • Connect BIA outputs and key data insights to the broader value argument
  • Highlight benefits, risks, and areas of uncertainty in a balanced and policy-relevant manner
Did you miss Module 4? You can catch up by viewing the recording today!
  • Have an MDBriefCase account? Click here to watch Module 4
  • Have an RxBriefCase account (for pharmacists)? Click here to watch Module 4
Faculté
Dr. Abeer Al Rabayah
Dr. Abeer Al Rabayah
BSc Pharmacy, MBA, MS
Chair of the ISPOR HTA Roundtable for the Middle East and Africa

Module 5: Pharmaco-Economic Dossier Submission at SFDA
April 23, 2026 | 7:00 PM - 8:00 PM AST (Riyadh)

Module 5 brings together everything participants have built so far. This session focuses on how to assemble a complete, submission-ready HTA dossier that aligns with the requirements and expectations of SFDA and MOH.

Did you miss Module 5? You can catch up by viewing the recording today!
  • Have an MDBriefCase account? Click here to watch Module 5
  • Have an RxBriefCase account (for pharmacists)? Click here to watch Module 5
Faculté
Dr. Yazeed Alkhnizan
Dr. Yazeed Alkhnizan
B.Sc. Pharma. MSc
International Health Technology Assessment, Pricing and Reimbursement (IHTA). Senior pricing & Pharmacoeconomic Expert, SFDA
Dr. Mohammed Alowairdhi
Dr. Mohammed Alowairdhi
MSc, MBA
Director, Pricing and Pharmacoeconomic Directorate, SFDA

Module 6: Reviewing Dossiers Through the Eyes of the Evaluator
May 7, 2026 | 6:00 PM - 8:00 PM AST (Riyadh)

This session teaches delegates how HTA reviewers in the KSA assess dossiers, apply scoring criteria, and identify strengths and weaknesses in submissions.

Participants will gain a deeper understanding of what decision-makers look for, how evidence is weighed, and what can influence pricing and reimbursement outcomes.

This module also prepares participants for the Capstone Mega Forum in Riyadh on June 5-6.

Note: Attendance for the in-person event will be through direct invitation and subject to criteria of inclusion.

Faculté
Dr. Yazeed Alkhnizan
Dr. Yazeed Alkhnizan
B.Sc. Pharma. MSc
International Health Technology Assessment, Pricing and Reimbursement (IHTA). Senior pricing & Pharmacoeconomic Expert, SFDA
Dr. Mohammed Alowairdhi
Dr. Mohammed Alowairdhi
MSc, MBA
Director, Pricing and Pharmacoeconomic Directorate, SFDA
Prof. David Strain
Prof. David Strain
MB, ChB, BSc (Hons) MD, FRCP

Module 7: In-person summit. Day 1: Strategic Foundations & The HTA Vision 2030
Friday, June 5, 2026 | 1:00 PM – 8:00 PM AST (Riyadh)

Aligning public sector leadership with the National HTA Vision, bridging the gap between regulatory guidelines and practical procurement, and establishing a common ground for pricing transparency.

Faculté
icon-user
Prof. David Strain
icon-user
Dr. Dalia Dawood

Module 8: In-person summit. Day 2: Collaborative Workshops & Implementation Excellence
Saturday, June 6, 2026 | 9:00 AM – 5:00 PM AST (Riyadh)

Translating HTA theory into actionable results through simulation labs and defining the specific criteria required for successful formulary inclusion in the 2026/27 cycle.

Faculté
icon-user
Dr. Mohammed Alshenawi
icon-user
Dr. Fatmah Alyami
icon-user
Dr.Mohamed Alowardi
icon-user
Prof Ahme Aljedaie
icon-user
Prof David Strain
icon-user
Dr Rayan Barakati (Guidelines and Protocols)
icon-user
Dr.Wejdan Abo Ras (MOH)
Program Chairs
Dr. Mohammed Alshennawi
Dr. Mohammed Alshennawi
B.Sc. Pharm., MBA
Prof. Ahmed Aljedaie
Prof. Ahmed Aljedaie
Pharm.D, BCPS, FCCP, FAST, FASHP
Educational Partners
ije7i0kazkt3m0v4hyene6vnudu4o6fm
SSCP_Logo_Final-002-1024x343-1
university-of-exeter
SPONSORS
Platinum Sponsors
AmgenBlueLogo@2x
corp-logo_bg_bayer-cross_basic_150dpi_on-screen_rgb 4
Gold Sponsors
Boehringer_Logo
Silver Sponsors
AstraZeneca-logo
Novartis-Logo.wine